Symrise (SY1) Q3 2025 TU earnings summary

Executive summary

• Achieved 1.4% organic sales growth in Q3 2025 and 2.6% for the first nine months, driven by volume increases and transformation initiatives, despite challenging macroeconomic and geopolitical conditions.

• Continued execution of the ONE Symrise Strategy and ONE SYM Transformation, focusing on efficiency, innovation, and portfolio optimization.

• Realized €30 million in cost savings year-to-date, on track for €40 million by year-end.

• Successfully placed a €800 million, 7-year bond at a 3.25% coupon, enhancing financial flexibility and supporting early debt refinancing.

Financial highlights

• Q3 2025 reported sales were €1,223 million, with a negative €54 million impact from portfolio and FX effects.

• Year-to-date 2025 sales reached €3,776 million, reflecting 2.6% organic growth.

• Taste, Nutrition & Health segment Q3 revenue: €750 million; Scent & Care segment Q3 revenue: €473 million.

• FX headwinds and currency devaluations significantly impacted reported sales.

Outlook and guidance

• Full-year 2025 organic growth guidance revised to 2.3%-3.3% from 3.0%-5.0% due to market volatility and softer demand.

• EBITDA margin target reaffirmed at approximately 21.5%.

• Business Free Cash Flow expected to be about 14% of sales.

• Mid-term 2028 targets: 5%-7% organic growth CAGR, 21%-23% EBITDA margin, >14% free cash flow as % of sales.